ClinicalTrials.gg

Program

400mg of TQB3909 tablets

A development code. Also written as “600mg of TQB3909 tablets”.

In Sino Biopharmaceutical’s pipeline, BCL-2抑制剂. Its studies are mostly in Lymphoma, Mantle-Cell, led by Sino Biopharmaceutical.

Furthest: phase 2, since Oct 24, 20231 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical10 open or runningphase 2since Oct 24, 2023Oct 24, 2023none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQB3909, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 24, 2023First study: phase 2 study in Lymphoma, Mantle-CellFirst studyNCT06106841 · 19 enrolled · China

TargetBeta

“BCL-2抑制剂”the company's pipeline, read by Claude · source

Other programs on BCL2

ProgramCompanyFurthest phaseStudies
venetoclaxruleAbbViephase 483
Bcl-2 Inhibitor TQB3909Sino Biopharmaceuticalphase 38
lacutoclaxruleLupeng Pharmaceuticalphase 24
surzetoclaxAbbViephase 23
surzetoclaxAbbViephase 12
FXS0683Fosun Pharmaphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06106841Lymphoma, Mantle-Cell · China2TerminatedOct 16, 202419

How it is read

Names in the registry

  • “400mg of TQB3909 tablets”, 1 entry
  • “600mg of TQB3909 tablets”, 1 entry

Codes read as this program: TQB3909.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.